A Phase 2 interventional study of Placebo Comparator and Experimental: Seladelpar 50 mg in Primary Biliary Cirrhosis (PBC), sponsored by Gilead Sciences. Terminated at 49 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences — 2 open to participants now, 3 under way, 2 of them phase 3. Liver Cirrhosis, Biliary · Gilead Sciences.
Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, this one is the 9th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 2, and was the 1st registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →2 of the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences are open now, in 12 countries. Recruiting first, the newest first:
Gilead Sciences · Sites in United States
Ages 18–75
Gilead Sciences · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 126 across the 10 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Liver Cirrhosis, Biliary by Gilead Sciences, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the effect of seladelpar (MBX-8025) on alkaline phosphatase (AP) levels in participants with primary biliary cirrhosis (PBC).
Primary:
To evaluate the effect of MBX-8025 on Alkaline Phosphatase (AP) levels
Secondary:
To evaluate the safety and tolerability of MBX-8025 in subjects with Primary Biliary Cirrhosis (PBC) To evaluate the effects of MBX-8025 on Primary Biliary Cirrhosis (PBC) response criteria To evaluate the effects of MBX-8025 on other markers of liver function, lipids, pruritus and Quality of Life (QoL)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female with a diagnosis of PBC, by at least two of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 2 placebo-to-match (PTM) seladelpar capsules, orally, once daily for 12 weeks.
Drug: Placebo Comparator
Participants received seladelpar 50 mg capsule (1 x 50 mg capsule) and a PTM seladelpar capsule, orally, once daily for 12 weeks.
Drug: Placebo Comparator · Drug: Experimental: Seladelpar 50 mg
Participants received seladelpar 200 mg capsules (2 x 100 mg capsules), orally, once daily for 12 weeks.
Drug: Experimental: Seladelpar / MBX-8025 200 mg
Placebo Capsule
Also known as: Placebo
Seladelpar 50 mg capsule
Also known as: MBX-8025, Livdelzi®
Drug page: Seladelpar
Seladelpar 100 mg capsules
Also known as: MBX-8025, Livdelzi®
Baseline Alkaline Phosphatase (AP) Levels
Baseline for AP level was defined as the mean between assessments at Visit 1 (Week -4 to Week 0) and Visit 2 (Week 0).
Time frame: Baseline
Percent Change From Baseline in Alkaline Phosphatase (AP) Levels
Percent change in AP serum levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by last observation carried forward (LOCF). Baseline for AP level was defined as the mean between assessments at Visit 1 (Week -4 to Week 0) and Visit 2 (Week 0).
Time frame: Baseline, Week 12
Percentage of Participants With Response as Determined by Composite Endpoint of Alkaline Phosphatase and Total Bilirubin
Participants were defined as responders for the composite endpoint of AP and total bilirubin if their AP level was \<1.67 × upper limit of normal (ULN) and had decreased at least 15% from their Baseline level and their total bilirubin value was within the normal range \[0.1-1.1 milligrams/deciliter (mg/dL)\].
Time frame: Week 12
Percent Change From Baseline in Aspartate Aminotransferase (AST)
Percentage change in AST levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for AST level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in Alanine Aminotransferase (ALT)
Percentage change in ALT levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for ALT level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in Gamma-glutamyl Transferase (GGT)
Percentage change in GGT levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for GGT level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in 5'Nucleotidase (5NT)
Percentage change in 5'Nucleotidase levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for 5NT level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in Total Bilirubin
Percentage change in total bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for total bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in Conjugated Bilirubin
Percentage change in conjugated bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for conjugated bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in Unconjugated Bilirubin
Percentage change in unconjugated bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for unconjugated bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in Bone-specific AP Levels
Percentage change in bone-specific AP levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for bone-specific level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in Triglycerides (TG)
Percentage change in TG levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for TG level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in Total Cholesterol (TC)
Percentage change in TC levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for TC level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)
Percentage change in HDL-C levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for HDL-C level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C)
Percentage change in LDL-C levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for LDL-C level was defined as the last non-missing assessments prior to or on the date of the first study dose.
Time frame: Baseline, Week 12
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris I)
Published criteria for response to treatment in PBC included Paris I criteria. For Paris I, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 3x ULN and AST ≤ 2x ULN and Total Bilirubin ≤ 1 mg/dL. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.
Time frame: Week 12
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris II)
Published criteria for response to treatment in PBC included Paris II criteria. For Paris II, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.5x ULN and AST ≤ 1.5x ULN and Total Bilirubin ≤ 1 mg/dL. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.
Time frame: Week 12
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto I)
Published criteria for response to treatment in PBC included Toronto I criteria. For Toronto I, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.67x ULN. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.
Time frame: Week 12
Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto II)
Published criteria for response to treatment in PBC included Toronto II criteria. For Toronto II, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.76x ULN. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.
Time frame: Week 12
United Kingdom-Primary Biliary Cirrhosis/Cholangitis (UK-PBC) Risk Score
The UK-PBC Risk Score was used to estimate the risk that a PBC participant would develop liver failure that would require liver transplantation within 5, 10 or 15 years from diagnosis. The UK-PBC Risk Score calculation was adapted based on the AP assessment, transaminases (refers to the ALT, where available, otherwise the AST assessment) and total bilirubin assessment respectively at end of treatment divided by its upper limits of the corresponding normal ranges; "albumin" and "platelet" refer to the baseline values of these parameters divided by their corresponding lower limits of normal ranges. Missing assessments at end of treatment was imputed by last observation carried forward (LOCF). The UK-PBC risk scores for 5, 10 and 15 years was calculated for each treatment group
Time frame: Week 12
Change From Baseline in 5-Dimension (5-D) Itch Scale Score
The 5-D itch scale was used to for the multidimensional quantification of pruritus over time. It assessed five aspects of itching: degree, duration, direction, disability, and distribution.The 5-D itch Scale is a measure of itching that has been validated in patients with chronic pruritus to detect changes over time. A 5-D itch scale score typically ranges from 5 to 25 with a higher score indicating greater itch severity, where 5 represents no pruritus (itching) and 25 represents the most severe pruritus; Each dimension is scored separately, and the scores are added together to get a total 5-D itch score. Higher scores indicate worsening of itching. The total 5-D itch Scale score change from Baseline was calculated. Baseline for 5-D itch scale was defined as the last non-missing assessments prior to or on the date of the first study dose. Missing assessments at end of treatment was imputed by LOCF.
Time frame: Baseline, Week 12
Change From Baseline in Pruritus Visual Analog Scale (VAS) Score
VAS was used to measure pruritis in participants with PBC. Participants placed a mark representing their level of itching since the previous measurement on a 100-mm VAS with 0 indicating no itching and 100 mm indicating the worst possible itching. Higher scores indicated worsening of itching The change from Baseline was presented by treatment group. Baseline for VAS score was defined as the last non-missing assessments prior to or on the date of the first study dose. Missing assessments at end of treatment was imputed by LOCF.
Time frame: Baseline, Week 12
Change From Baseline in PBC-40 Quality of Life Questionnaire
The PBC-40 questionnaire was used to evaluate health-related quality of life measures, specifically fatigue. The PBC-40 questionnaire is a disease-specific tool developed to specifically measure the psychometric profile of PBC patients. It consists of 40 items divided into the six domains relevant to PBC including Cognitive, Social, EmotionalFunction, Fatigue, Itch, and Other Symptoms/General Questions. Items are scored from 1 to 5 and individual items scores are summed to give a total domain score. PBC 40 QoL domain score ranges are:Cognitive (6-30), Emotional Function (3-15),Fatigue (11-55), Itch (3-15),Social (10-50),Symptoms (7-35).Higher scores represent high impact and lower scores low impact of PBC on quality of life.The change and percentage change from Baseline for individual domain score at end of treatment were reported. Baseline for PBC-40 questionnaire was the last non-missing assessments prior to or on the date of the first study dose.Missing assessments imputed by LOCF.
Time frame: Baseline, Week 12
Participants were enrolled at study sites in Canada, Germany, the United Kingdom, and the United States.
| Milestone | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Started | 13 | 14 | 14 |
| Completed | 2 | 4 | 4 |
| Not completed | 11 | 10 | 10 |
| Withdrew: Adverse event | 3 | 0 | 0 |
| Withdrew: Randomized but never treated | 1 | 1 | 1 |
| Withdrew: Withdrawal of informed consent | 1 | 0 | 0 |
| Withdrew: Reason not specified | 6 | 9 | 9 |
Baseline for AP level was defined as the mean between assessments at Visit 1 (Week -4 to Week 0) and Visit 2 (Week 0).
| units per liter (U/L) | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Baseline Alkaline Phosphatase (AP) Levels | 248.3 ± 88.69 | 311.6 ± 94.83 | 232.8 ± 72.51 |
Percent change in AP serum levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by last observation carried forward (LOCF). Baseline for AP level was defined as the mean between assessments at Visit 1 (Week -4 to Week 0) and Visit 2 (Week 0).
| percent change in AP levels | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Alkaline Phosphatase (AP) Levels | -62.83 ± 4.312 | -53.21 ± 3.961 | -1.84 ± 4.020 |
Participants were defined as responders for the composite endpoint of AP and total bilirubin if their AP level was \<1.67 × upper limit of normal (ULN) and had decreased at least 15% from their Baseline level and their total bilirubin value was within the normal range \[0.1-1.1 milligrams/deciliter (mg/dL)\].
| percentage of participants | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With Response as Determined by Composite Endpoint of Alkaline Phosphatase and Total Bilirubin | 100 | 69.2 | 8.3 |
Percentage change in AST levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for AST level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in AST levels | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Aspartate Aminotransferase (AST) | 232.69 ± 77.409 | 130.81 ± 66.933 | -2.02 ± 69.364 |
Percentage change in ALT levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for ALT level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in ALT levels | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Alanine Aminotransferase (ALT) | 181.11 ± 77.864 | 111.83 ± 68.061 | -4.67 ± 69.632 |
Percentage change in GGT levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for GGT level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in GGT levels | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Gamma-glutamyl Transferase (GGT) | -47.17 ± 9.084 | -42.60 ± 7.796 | -1.83 ± 7.889 |
Percentage change in 5'Nucleotidase levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for 5NT level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in 5'Nucleotidase levels | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in 5'Nucleotidase (5NT) | -34.35 ± 8.446 | -24.92 ± 7.148 | -0.08 ± 7.305 |
Percentage change in total bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for total bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in total bilirubin levels | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Total Bilirubin | 1.40 ± 6.384 | -16.79 ± 5.586 | -4.79 ± 5.793 |
Percentage change in conjugated bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for conjugated bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in conjugated bilirubin | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Conjugated Bilirubin | 42.30 ± 10.213 | 2.00 ± 8.932 | 10.84 ± 9.296 |
Percentage change in unconjugated bilirubin levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for unconjugated bilirubin level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in unconjugated bilirubin | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Unconjugated Bilirubin | -11.86 ± 6.197 | -23.04 ± 5.431 | -8.89 ± 5.620 |
Percentage change in bone-specific AP levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for bone-specific level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in bone-specific AP level | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Bone-specific AP Levels | -50.39 ± 4.837 | -39.09 ± 4.355 | -4.43 ± 4.544 |
Percentage change in TG levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for TG level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in TG levels | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Triglycerides (TG) | -7.11 ± 9.415 | -30.27 ± 8.243 | 7.04 ± 8.617 |
Percentage change in TC levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for TC level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in TC levels | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Total Cholesterol (TC) | -16.43 ± 3.250 | -8.44 ± 2.774 | -0.32 ± 2.905 |
Percentage change in HDL-C levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for HDL-C level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in HDL-C levels | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) | -13.06 ± 4.326 | 3.44 ± 3.747 | 4.33 ± 3.884 |
Percentage change in LDL-C levels from Baseline to the end of treatment was analyzed. For missing postbaseline data, the last non-missing postbaseline value on treatment was carried forward, with missing assessments imputed by LOCF. Baseline for LDL-C level was defined as the last non-missing assessments prior to or on the date of the first study dose.
| percent change in LDL-C levels | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) | -17.63 ± 4.372 | -12.83 ± 3.763 | -2.78 ± 3.958 |
Published criteria for response to treatment in PBC included Paris I criteria. For Paris I, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 3x ULN and AST ≤ 2x ULN and Total Bilirubin ≤ 1 mg/dL. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.
| Participants | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris I) | 2 | 2 | 2 |
Published criteria for response to treatment in PBC included Paris II criteria. For Paris II, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.5x ULN and AST ≤ 1.5x ULN and Total Bilirubin ≤ 1 mg/dL. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.
| Participants | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Paris II) | 5 | 8 | 9 |
Published criteria for response to treatment in PBC included Toronto I criteria. For Toronto I, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.67x ULN. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.
| Participants | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto I) | 0 | 3 | 7 |
Published criteria for response to treatment in PBC included Toronto II criteria. For Toronto II, the criteria used to measure the PBC participants' response to study treatment was: AP ≤ 1.76x ULN. Participants who satisfied the criteria were defined as responders and those who did not were considered nonresponders if all the elements had non-missing assessments at that visit. The number of nonresponders were reported, the missing assessments were imputed by LOCF.
| Participants | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Number of Participants Who Were Non-responders as Determined by Published PBC Response Criteria (Toronto II) | 0 | 2 | 7 |
The UK-PBC Risk Score was used to estimate the risk that a PBC participant would develop liver failure that would require liver transplantation within 5, 10 or 15 years from diagnosis. The UK-PBC Risk Score calculation was adapted based on the AP assessment, transaminases (refers to the ALT, where available, otherwise the AST assessment) and total bilirubin assessment respectively at end of treatment divided by its upper limits of the corresponding normal ranges; "albumin" and "platelet" refer to the baseline values of these parameters divided by their corresponding lower limits of normal ranges. Missing assessments at end of treatment was imputed by last observation carried forward (LOCF). The UK-PBC risk scores for 5, 10 and 15 years was calculated for each treatment group
| percentage risk | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| UK-PBC Risk Score by 5 years | 1.3642 ± 0.95452 | 1.8530 ± 2.32301 | 3.1102 ± 5.1892 |
| UK-PBC Risk Score by 10 years | 3.9796 ± 2.74081 | 5.2712 ± 6.31842 | 8.3004 ± 12.51699 |
| UK-PBC Risk Score by 15 years | 6.4392 ± 4.36737 | 8.3379 ± 9.57184 | 12.4804 ± 17.05244 |
The 5-D itch scale was used to for the multidimensional quantification of pruritus over time. It assessed five aspects of itching: degree, duration, direction, disability, and distribution.The 5-D itch Scale is a measure of itching that has been validated in patients with chronic pruritus to detect changes over time. A 5-D itch scale score typically ranges from 5 to 25 with a higher score indicating greater itch severity, where 5 represents no pruritus (itching) and 25 represents the most severe pruritus; Each dimension is scored separately, and the scores are added together to get a total 5-D itch score. Higher scores indicate worsening of itching. The total 5-D itch Scale score change from Baseline was calculated. Baseline for 5-D itch scale was defined as the last non-missing assessments prior to or on the date of the first study dose. Missing assessments at end of treatment was imputed by LOCF.
| score on a scale | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline in 5-Dimension (5-D) Itch Scale Score | -0.9 ± 1.31 | 0.5 ± 1.15 | 0.2 ± 1.25 |
VAS was used to measure pruritis in participants with PBC. Participants placed a mark representing their level of itching since the previous measurement on a 100-mm VAS with 0 indicating no itching and 100 mm indicating the worst possible itching. Higher scores indicated worsening of itching The change from Baseline was presented by treatment group. Baseline for VAS score was defined as the last non-missing assessments prior to or on the date of the first study dose. Missing assessments at end of treatment was imputed by LOCF.
| score on a scale | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Pruritus Visual Analog Scale (VAS) Score | 0.9 ± 7.54 | -0.7 ± 6.35 | 8.3 ± 6.42 |
The PBC-40 questionnaire was used to evaluate health-related quality of life measures, specifically fatigue. The PBC-40 questionnaire is a disease-specific tool developed to specifically measure the psychometric profile of PBC patients. It consists of 40 items divided into the six domains relevant to PBC including Cognitive, Social, EmotionalFunction, Fatigue, Itch, and Other Symptoms/General Questions. Items are scored from 1 to 5 and individual items scores are summed to give a total domain score. PBC 40 QoL domain score ranges are:Cognitive (6-30), Emotional Function (3-15),Fatigue (11-55), Itch (3-15),Social (10-50),Symptoms (7-35).Higher scores represent high impact and lower scores low impact of PBC on quality of life.The change and percentage change from Baseline for individual domain score at end of treatment were reported. Baseline for PBC-40 questionnaire was the last non-missing assessments prior to or on the date of the first study dose.Missing assessments imputed by LOCF.
| score on a scale | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| Cognitive Domain Score | 2.6 ± 0.96 | 0.9 ± 0.76 | -0.8 ± 0.80 |
| Social Domain Score | 3.2 ± 1.32 | 0.3 ± 1.06 | -0.5 ± 1.09 |
| Emotional Function Domain Score | 0.4 ± 0.73 | 0.4 ± 0.58 | 0.0 ± 0.62 |
| Fatigue Domain Score | -0.3 ± 1.50 | 2.3 ± 1.20 | -1.9 ± 1.26 |
| Itch Domain Score | -0.6 ± 0.81 | 0.3 ± 0.65 | -0.4 ± 0.67 |
| Symptoms Domain Score | 1.1 ± 0.76 | 0.9 ± 0.62 | -1.5 ± 0.64 |
Collected over All-cause mortality: Up to 16.4 weeks; Adverse events: Up to 14.7 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Seladelpar 200 mg | 0/13 (0%) | 0/12 (0%) | 10/12 (83.3%) |
| Seladelpar 50 mg | 0/14 (0%) | 0/13 (0%) | 11/13 (84.6%) |
| Placebo | 0/14 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| Event | Seladelpar 200 mg | Seladelpar 50 mg | Placebo |
|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 1/12 | 4/13 | 1/13 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/12 | 0/13 | 0/13 |
| NauseaGastrointestinal disorders | 1/12 | 3/13 | 1/13 |
| Alanine aminotransferase increasedInvestigations | 2/12 | 0/13 | 0/13 |
| Aspartate aminotransferase increasedInvestigations | 2/12 | 0/13 | 0/13 |
| MyalgiaMusculoskeletal and connective tissue disorders | 2/12 | 0/13 | 1/13 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 1/13 | 2/13 |
| DyspepsiaGastrointestinal disorders | 1/12 | 2/13 | 0/13 |
| DizzinessNervous system disorders | 0/12 | 2/13 | 1/13 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/12 | 2/13 | 0/13 |
The Safety Population was defined as any randomized participant who received at least 1 dose of medication.
| Age, Categorical(Participants) | Seladelpar 200 mg | Seladelpar 50 mg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 9 | 12 | 12 | 33 |
| >=65 years | 3 | 1 | 1 | 5 |
| Age, Continuous(years) | Seladelpar 200 mg | Seladelpar 50 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 57 ± 11.4 | 54 ± 7.4 | 55 ± 10.1 | 55 ± 9.5 |
| Sex: Female, Male(Participants) | Seladelpar 200 mg | Seladelpar 50 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 12 | 12 | 12 | 36 |
| Male | 0 | 1 | 1 | 2 |
| Ethnicity (NIH/OMB)(Participants) | Seladelpar 200 mg | Seladelpar 50 mg | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 12 | 12 | 13 | 37 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Seladelpar 200 mg | Seladelpar 50 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 0 | 2 |
| White | 10 | 12 | 13 | 35 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Seladelpar 200 mg | Seladelpar 50 mg | Placebo | Total |
|---|---|---|---|---|
| United States | 6 | 5 | 6 | 17 |
| United Kingdom | 2 | 4 | 3 | 9 |
| Germany | 3 | 2 | 3 | 8 |
| Canada | 1 | 2 | 1 | 4 |
Ran from Nov 2015 to primary completion in Jul 2016, 7 months.
Results were first posted in Feb 2025, 8 years 7 months after primary completion. A results delay was requested in Jan 2018.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seladelpar